Prostaglandin analogs in the treatment of glaucoma

Thomas W. Hejkal, Carl B. Camras

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Prostaglandin (PG) analogs are some of the most recent additions to the list of ocular hypotensive medications. Two analogs of naturally occurring PGs are available commercially, isopropyl unoprostone (Rescula [Ciba Vision, Atlanta, GA]) and latanoprost (Xalatan [Pharmacia and Upjohn, Bridgewater, NJ]). Presently, latanoprost 0.005% is the only PG analog commercially available in the United States. These agents have been shown to be the most effective topical medications for reducing intraocular pressure. They have a different mechanism of action than other ocular hypotensives, and act primarily by increasing uveoscleral outflow. Because of this, PGs have a substantial additive effect when used with agents that reduce aqueous production (eg, beta blockers or carbonic anhydrase inhibitors) or that increase trabecular outflow facility (eg, pilocarpine). Local side effects include mild conjunctival hyperemia and local irritation, darkening of iris color, increased growth of eyelashes, and a possible association with cystoid macular edema or iritis in some patients with other risk factors. No systemic side effects have been proven to be caused by latanoprost. Recommended dosing is once daily at bedtime.

Original languageEnglish (US)
Pages (from-to)114-123
Number of pages10
JournalSeminars in Ophthalmology
Volume14
Issue number3
DOIs
StatePublished - Sep 1999

Fingerprint

latanoprost
Synthetic Prostaglandins
Glaucoma
Iritis
Eyelashes
Carbonic Anhydrase Inhibitors
Pilocarpine
Macular Edema
Hyperemia
Iris
Therapeutics
Intraocular Pressure
Color
Growth

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Prostaglandin analogs in the treatment of glaucoma. / Hejkal, Thomas W.; Camras, Carl B.

In: Seminars in Ophthalmology, Vol. 14, No. 3, 09.1999, p. 114-123.

Research output: Contribution to journalReview article

Hejkal, Thomas W. ; Camras, Carl B. / Prostaglandin analogs in the treatment of glaucoma. In: Seminars in Ophthalmology. 1999 ; Vol. 14, No. 3. pp. 114-123.
@article{89562927a6664125afc58fb9d066dd08,
title = "Prostaglandin analogs in the treatment of glaucoma",
abstract = "Prostaglandin (PG) analogs are some of the most recent additions to the list of ocular hypotensive medications. Two analogs of naturally occurring PGs are available commercially, isopropyl unoprostone (Rescula [Ciba Vision, Atlanta, GA]) and latanoprost (Xalatan [Pharmacia and Upjohn, Bridgewater, NJ]). Presently, latanoprost 0.005{\%} is the only PG analog commercially available in the United States. These agents have been shown to be the most effective topical medications for reducing intraocular pressure. They have a different mechanism of action than other ocular hypotensives, and act primarily by increasing uveoscleral outflow. Because of this, PGs have a substantial additive effect when used with agents that reduce aqueous production (eg, beta blockers or carbonic anhydrase inhibitors) or that increase trabecular outflow facility (eg, pilocarpine). Local side effects include mild conjunctival hyperemia and local irritation, darkening of iris color, increased growth of eyelashes, and a possible association with cystoid macular edema or iritis in some patients with other risk factors. No systemic side effects have been proven to be caused by latanoprost. Recommended dosing is once daily at bedtime.",
author = "Hejkal, {Thomas W.} and Camras, {Carl B.}",
year = "1999",
month = "9",
doi = "10.3109/08820539909061464",
language = "English (US)",
volume = "14",
pages = "114--123",
journal = "Seminars in Ophthalmology",
issn = "0882-0538",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Prostaglandin analogs in the treatment of glaucoma

AU - Hejkal, Thomas W.

AU - Camras, Carl B.

PY - 1999/9

Y1 - 1999/9

N2 - Prostaglandin (PG) analogs are some of the most recent additions to the list of ocular hypotensive medications. Two analogs of naturally occurring PGs are available commercially, isopropyl unoprostone (Rescula [Ciba Vision, Atlanta, GA]) and latanoprost (Xalatan [Pharmacia and Upjohn, Bridgewater, NJ]). Presently, latanoprost 0.005% is the only PG analog commercially available in the United States. These agents have been shown to be the most effective topical medications for reducing intraocular pressure. They have a different mechanism of action than other ocular hypotensives, and act primarily by increasing uveoscleral outflow. Because of this, PGs have a substantial additive effect when used with agents that reduce aqueous production (eg, beta blockers or carbonic anhydrase inhibitors) or that increase trabecular outflow facility (eg, pilocarpine). Local side effects include mild conjunctival hyperemia and local irritation, darkening of iris color, increased growth of eyelashes, and a possible association with cystoid macular edema or iritis in some patients with other risk factors. No systemic side effects have been proven to be caused by latanoprost. Recommended dosing is once daily at bedtime.

AB - Prostaglandin (PG) analogs are some of the most recent additions to the list of ocular hypotensive medications. Two analogs of naturally occurring PGs are available commercially, isopropyl unoprostone (Rescula [Ciba Vision, Atlanta, GA]) and latanoprost (Xalatan [Pharmacia and Upjohn, Bridgewater, NJ]). Presently, latanoprost 0.005% is the only PG analog commercially available in the United States. These agents have been shown to be the most effective topical medications for reducing intraocular pressure. They have a different mechanism of action than other ocular hypotensives, and act primarily by increasing uveoscleral outflow. Because of this, PGs have a substantial additive effect when used with agents that reduce aqueous production (eg, beta blockers or carbonic anhydrase inhibitors) or that increase trabecular outflow facility (eg, pilocarpine). Local side effects include mild conjunctival hyperemia and local irritation, darkening of iris color, increased growth of eyelashes, and a possible association with cystoid macular edema or iritis in some patients with other risk factors. No systemic side effects have been proven to be caused by latanoprost. Recommended dosing is once daily at bedtime.

UR - http://www.scopus.com/inward/record.url?scp=0032863922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032863922&partnerID=8YFLogxK

U2 - 10.3109/08820539909061464

DO - 10.3109/08820539909061464

M3 - Review article

C2 - 10790575

AN - SCOPUS:0032863922

VL - 14

SP - 114

EP - 123

JO - Seminars in Ophthalmology

JF - Seminars in Ophthalmology

SN - 0882-0538

IS - 3

ER -